Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
Identifieur interne : 000797 ( PubMed/Curation ); précédent : 000796; suivant : 000798Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
Auteurs : Naif Khalaf Alharbi [Arabie saoudite]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2019.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux, Embryon de poulet, Essais cliniques comme sujet, Humains, Immunogénicité des vaccins, Régions promotrices (génétique), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins synthétiques (immunologie), Vecteurs génétiques, Virus de la vaccine (génétique), Virus de la vaccine (immunologie).
- MESH :
- génétique : Vaccins antiviraux, Virus de la vaccine.
- immunologie : Vaccins antiviraux, Vaccins synthétiques, Virus de la vaccine.
- Animaux, Anticorps antiviraux, Embryon de poulet, Essais cliniques comme sujet, Humains, Immunogénicité des vaccins, Régions promotrices (génétique), Vecteurs génétiques.
English descriptors
- KwdEn :
- MESH :
- chemical , genetics : Viral Vaccines.
- chemical , immunology : Vaccines, Synthetic, Viral Vaccines.
- chemical : Antibodies, Viral.
- genetics : Vaccinia virus.
- immunology : Vaccinia virus.
- Animals, Chick Embryo, Clinical Trials as Topic, Genetic Vectors, Humans, Immunogenicity, Vaccine, Promoter Regions, Genetic.
Abstract
Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV/AIDS, influenza, and tuberculosis, MERS-CoV, and Ebola virus infection. There is accumulating data from many preclinical and clinical studies that highlights the excellent safety and immunogenicity of MVA. However, due to the complex nature of many pathogens and their pathogenicity, MVA vectored vaccine candidates need to be optimised to improve their immunogenicity. One of the main approaches to improve MVA immunogenicity focuses on optimising poxviral promoters that drive recombinant vaccine antigens, encoded within recombinant MVA vector genome. A number of promoters were described or optimised to improve the development of MVA based vaccines such as p7.5, pF11, and mH5 promoters. This review focuses on poxviral promoters, their optimisation, genetic stability, and clinical use.
DOI: 10.1080/21645515.2018.1513439
PubMed: 30148692
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000797
Links to Exploration step
pubmed:30148692Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.</title><author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name><affiliation wicri:level="1"><nlm:affiliation>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh , Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh </wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30148692</idno><idno type="pmid">30148692</idno><idno type="doi">10.1080/21645515.2018.1513439</idno><idno type="wicri:Area/PubMed/Corpus">000797</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000797</idno><idno type="wicri:Area/PubMed/Curation">000797</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000797</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.</title><author><name sortKey="Alharbi, Naif Khalaf" sort="Alharbi, Naif Khalaf" uniqKey="Alharbi N" first="Naif Khalaf" last="Alharbi">Naif Khalaf Alharbi</name><affiliation wicri:level="1"><nlm:affiliation>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh , Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh </wicri:regionArea></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral</term><term>Chick Embryo</term><term>Clinical Trials as Topic</term><term>Genetic Vectors</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Promoter Regions, Genetic</term><term>Vaccines, Synthetic (immunology)</term><term>Vaccinia virus (genetics)</term><term>Vaccinia virus (immunology)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux</term><term>Embryon de poulet</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Régions promotrices (génétique)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Vecteurs génétiques</term><term>Virus de la vaccine (génétique)</term><term>Virus de la vaccine (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Vaccinia virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antiviraux</term><term>Virus de la vaccine</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term><term>Virus de la vaccine</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Vaccinia virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chick Embryo</term><term>Clinical Trials as Topic</term><term>Genetic Vectors</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Promoter Regions, Genetic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux</term><term>Embryon de poulet</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Régions promotrices (génétique)</term><term>Vecteurs génétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV/AIDS, influenza, and tuberculosis, MERS-CoV, and Ebola virus infection. There is accumulating data from many preclinical and clinical studies that highlights the excellent safety and immunogenicity of MVA. However, due to the complex nature of many pathogens and their pathogenicity, MVA vectored vaccine candidates need to be optimised to improve their immunogenicity. One of the main approaches to improve MVA immunogenicity focuses on optimising poxviral promoters that drive recombinant vaccine antigens, encoded within recombinant MVA vector genome. A number of promoters were described or optimised to improve the development of MVA based vaccines such as p7.5, pF11, and mH5 promoters. This review focuses on poxviral promoters, their optimisation, genetic stability, and clinical use.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30148692</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.</ArticleTitle><Pagination><MedlinePgn>203-209</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2018.1513439</ELocationID><Abstract><AbstractText>Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV/AIDS, influenza, and tuberculosis, MERS-CoV, and Ebola virus infection. There is accumulating data from many preclinical and clinical studies that highlights the excellent safety and immunogenicity of MVA. However, due to the complex nature of many pathogens and their pathogenicity, MVA vectored vaccine candidates need to be optimised to improve their immunogenicity. One of the main approaches to improve MVA immunogenicity focuses on optimising poxviral promoters that drive recombinant vaccine antigens, encoded within recombinant MVA vector genome. A number of promoters were described or optimised to improve the development of MVA based vaccines such as p7.5, pF11, and mH5 promoters. This review focuses on poxviral promoters, their optimisation, genetic stability, and clinical use.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alharbi</LastName><ForeName>Naif Khalaf</ForeName><Initials>NK</Initials><Identifier Source="ORCID">0000-0002-6049-3383</Identifier><AffiliationInfo><Affiliation>a Infectious Disease Research Department , King Abdullah International Medical Research Center (KAIMRC) , Riyadh , Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002642" MajorTopicYN="N">Chick Embryo</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014616" MajorTopicYN="N">Vaccinia virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MVA</Keyword><Keyword MajorTopicYN="Y">immunogenicity</Keyword><Keyword MajorTopicYN="Y">poxviral vector</Keyword><Keyword MajorTopicYN="Y">promoter</Keyword><Keyword MajorTopicYN="Y">vaccine vector</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30148692</ArticleId><ArticleId IdType="doi">10.1080/21645515.2018.1513439</ArticleId><ArticleId IdType="pmc">PMC6363155</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Mol Biol. 1989 Dec 20;210(4):771-84</Citation><ArticleIdList><ArticleId IdType="pubmed">2515287</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 Aug;76(16):8318-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12134037</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 2005 Jan 3;201(1):95-104</Citation><ArticleIdList><ArticleId IdType="pubmed">15623576</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2013 Aug 12;8(8):e73511</Citation><ArticleIdList><ArticleId IdType="pubmed">23951355</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Jan 2;34(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">26616553</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2012;7(6):e40167</Citation><ArticleIdList><ArticleId IdType="pubmed">22761956</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Sep 6;31(39):4241-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23523410</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 1990 Apr;16(1):43-57</Citation><ArticleIdList><ArticleId IdType="pubmed">2161593</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2013 Mar 23;381(9871):1021-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23391465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2008 Apr;15(4):691-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18272665</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2140-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18245380</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 1989 Dec 20;210(4):749-69</Citation><ArticleIdList><ArticleId IdType="pubmed">2515286</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2015 Aug;96(8):2360-2371</Citation><ArticleIdList><ArticleId IdType="pubmed">25972354</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1985 Apr;54(1):30-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3973982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11513-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20534518</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 1990;112(3-4):139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2165765</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2293-2303</Citation><ArticleIdList><ArticleId IdType="pubmed">12917449</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2009;4(5):e5445</Citation><ArticleIdList><ArticleId IdType="pubmed">19421328</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2004 Dec 15;122(2):141-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15542137</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1988 Jun;62(6):1889-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2835495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2008 Jan 24;26(4):486-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18155813</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 May;74(9):4236-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10756037</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 May 22;24(21):4618-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16157428</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1989 Sep;63(9):3829-36</Citation><ArticleIdList><ArticleId IdType="pubmed">2547999</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 1986 Dec;16(12):1479-87</Citation><ArticleIdList><ArticleId IdType="pubmed">3493144</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Vaccines. 2008 Sep;7(7):889-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18767940</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2014 Oct;20(10):1126-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25194571</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Genes. 1990 Apr;3(4):355-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2349786</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2014;10(8):2235-44</Citation><ArticleIdList><ArticleId IdType="pubmed">25424927</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1986 Nov;60(2):436-49</Citation><ArticleIdList><ArticleId IdType="pubmed">3021979</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biotechniques. 1997 Dec;23(6):1094-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9421642</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 1981 Sep;25(3):805-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7285118</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci China C Life Sci. 2007 Apr;50(2):212-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17447028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1986 Oct;67 ( Pt 10):2067-82</Citation><ArticleIdList><ArticleId IdType="pubmed">3531399</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2012 Sep;8(9):1192-207</Citation><ArticleIdList><ArticleId IdType="pubmed">22906946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2011 Jun;85(12):5897-909</Citation><ArticleIdList><ArticleId IdType="pubmed">21490097</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Avian Dis. 1990 Jan-Mar;34(1):218-20</Citation><ArticleIdList><ArticleId IdType="pubmed">2157394</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Jan;82(2):652-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17977963</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71</Citation><ArticleIdList><ArticleId IdType="pubmed">14529359</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13980-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16172378</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 May 22;24(21):4554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16150517</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Z Immunitatsforsch Exp Klin Immunol. 1972 Sep;144(2):104-56</Citation><ArticleIdList><ArticleId IdType="pubmed">4282933</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2011;6(5):e20067</Citation><ArticleIdList><ArticleId IdType="pubmed">21603645</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1989 May;170(1):288-91</Citation><ArticleIdList><ArticleId IdType="pubmed">2541544</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 1997 Jun;66(1):135-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9220399</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3183-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9096367</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2015 May 26;10(5):e0127978</Citation><ArticleIdList><ArticleId IdType="pubmed">26011541</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Sep 6;31(39):4223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23746455</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin. 2010 Jan;6(1):78-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20061802</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 1996 Oct;14(15):1451-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8994321</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1988 Jan;69 ( Pt 1):35-47</Citation><ArticleIdList><ArticleId IdType="pubmed">2826668</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1998 May 10;244(2):365-96</Citation><ArticleIdList><ArticleId IdType="pubmed">9601507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1982 Aug;79(16):4927-31</Citation><ArticleIdList><ArticleId IdType="pubmed">6289324</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1987 Sep;68 ( Pt 9):2299-309</Citation><ArticleIdList><ArticleId IdType="pubmed">2821171</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Sep 6;31(39):4235-40</Citation><ArticleIdList><ArticleId IdType="pubmed">23523402</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2008 Jul 09;3(7):e2628</Citation><ArticleIdList><ArticleId IdType="pubmed">18612436</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90</Citation><ArticleIdList><ArticleId IdType="pubmed">219640</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1987 May;158(1):206-10</Citation><ArticleIdList><ArticleId IdType="pubmed">3472413</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2010 Sep;84(17):8743-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20538860</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1985 Sep 6;229(4717):981-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2992092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1990 Dec;64(12):6063-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2243387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2013 Dec;94(Pt 12):2771-2776</Citation><ArticleIdList><ArticleId IdType="pubmed">24077296</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1993 Sep;67(9):5394-401</Citation><ArticleIdList><ArticleId IdType="pubmed">8350402</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2010 Feb 10;28(6):1547-57</Citation><ArticleIdList><ArticleId IdType="pubmed">19969118</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1984 Feb;49(2):371-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6319738</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Jan;74(2):923-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10623755</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2009 Jul;83(14):7176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19420086</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000797 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000797 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:30148692
|texte= Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:30148692" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |